In Lipitor Showdown, Pfizer Settlement with Ranbaxy Saves Apotex Declaratory Judgment Claims

In litigation with Canadian generic manufacturer Apotex over its multibillion dollar cholesterol drug Lipitor, Pfizer failed to win the dismissal of Apotex's declaratory judgment claims—in part because it previously made a deal with Ranbaxy to block generic versions of Lipitor from coming to the market.

, The American Lawyer

In litigation with Canadian generic manufacturer Apotex over its multibillion dollar cholesterol drug Lipitor, Pfizer failed to win the dismissal of Apotex's declaratory judgment claims—in part because it previously made a deal with Ranbaxy to block generic versions of Lipitor from coming to the market.

This content has been archived. It is available exclusively through our partner LexisNexis®.

To view this content, please continue to Lexis Advance®.

Continue to Lexis Advance®

Not a Lexis Advance® Subscriber? Subscribe Now

Why am I seeing this?

LexisNexis® is now the exclusive third party online distributor of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® customers will be able to access and use ALM's content by subscribing to the LexisNexis® services via Lexis Advance®. This includes content from the National Law Journal®, The American Lawyer®, Law Technology News®, The New York Law Journal® and Corporate Counsel®, as well as ALM's other newspapers, directories, legal treatises, published and unpublished court opinions, and other sources of legal information.

ALM's content plays a significant role in your work and research, and now through this alliance LexisNexis® will bring you access to an even more comprehensive collection of legal content.

For questions call 1-877-256-2472 or contact us at customercare@alm.com